⚠️ Mechanism
Cranberry is a weak inhibitor of CYP3A4, which decreases metabolism of CYP3A4 substrates, potentially increasing their plasma concentrations and risk of adverse effects.
📋 Effect
Increased plasma levels of doxorubicin (chemotherapy), potentially leading to toxicity or enhanced adverse effects.
💊 Management
Monitor for increased adverse effects of doxorubicin. Dose reduction may be necessary. Consider alternative supplement or consult healthcare provider.
Plain Language Summary
This combination carries a moderate risk because cranberry can slow down how your body processes this chemotherapy drug. This may cause the medication to build up in your system, which could increase the chance of experiencing more severe side effects.
Source
Flockhart CYP450 Table (drug-interactions.medicine.iu.edu)
Supporting Research
Study of Oral Anthocyanins on Insulin Resistance
The Effect of Cranberry Extract Supplementation on Cardiovascular Risk Factors in Obese, Insulin Resistant Humans
Adverse Event Profile: Cranberry
Medical Disclaimer: This interaction record is for informational and educational purposes only and does not constitute medical advice. Drug-supplement interactions can be dangerous. Always consult your healthcare provider or pharmacist before combining any supplement with prescription medications. Do not stop or change any medication without professional guidance.